Support for VALID in the FDA Safety and Landmark Advancement Act Draft of 2022

May 23, 2022 | News


The letter below was addressed and emailed to Senators Burr and Murray on May 21, 2022:

We at the independent and nonprofit Center for Genomic Interpretation (CGI) are writing in support of the FDA Safety and Landmark Advancement Act draft, specifically the VALID Act of 2022 (Subtitle C). CGI’s nonprofit mission is to encourage careful stewardship of clinical genetics, genomics and precision medicine. In our work at CGI we regularly uncover patient harming errors in laboratory developed tests (LDT). We believe many of these errors would be prevented if clinical genetic and genomic tests were regulated by the FDA. Systematic as well as sporadic sources of error are brought to our attention by clinicians, patients, and laboratory whistle blowers. We also discover laboratory errors through the laboratory selection assessment work we do for health insurance and pharma companies. Based upon our experience, we do not believe the precision medicine industry can continue through self-policing (e.g. CAP) alone without causing additional and increasing harm to patients. Thus, FDA oversight is needed for precision medicine to widely succeed.

CGI wishes to stress the importance of regulatory oversight over clinical laboratory testing because major medical decisions are made based on genetic and other diagnostic test results. The LDT loophole has been used for years by diagnostic testing laboratories to dodge independent review and verification of test performance. LDT status was originally intended for small volume tests for rare conditions, where only a handful of samples would be processed per year and meeting FDA approval or clearance requirements would be practically impossible. However, the LDT status loophole has been broadly used by the clinical laboratory industry to offer unvalidated and frequently inaccurate testing to a large portion of the population.

We commend professional organizations such as CAP, AMP and ACMG for their role in providing guidelines, education and checklist resources to help laboratories make quality improvements. Unfortunately, these tools have not been enough to protect patients from preventable harm. And sometimes these organizations are not transparent with clinicians and the public concerning some of the harmful weaknesses of genetic and genomic laboratories. Many professional organization members also make excuses when quality issues are published independently by brave clinicians and researchers [see appended references].

Allowances have historically been made for less accurate clinical tests when the tests originate from laboratories that lack sufficient resources to produce consistently accurate diagnostics with demonstrated efficacy. We believe that only laboratories with sufficient resources to develop accurate and reliable tests, and those that can transparently demonstrate that their tests are safe and effective, should be allowed to market tests for clinical use. We believe FDA oversight would create a safer-for-patients market environment, and that innovation towards safe and effective tests would continue. The market will adapt. It always does.

Because of the serious risk of harm to the many patients who receive poor clinical laboratory testing, we strongly support the VALID Act of 2022 to prevent the clinical laboratory industry from continuing to offer tests to patients without any independent review of safety or effectiveness.


Dr. Julie Eggington

Abbreviations: LDT = Laboratory Developed Test, CAP = College of American Pathologists, AMP = Association for Molecular Pathology, ACMG = American College of Medical Genetics and Genomics

Appendix in the Attached Document: Supporting quotes and references

LinkedIn post with Copy of Letter sent to Senators

CONTACT CGI TODAY: Contact us today to learn more about how we can help you, your organization, your plan members and your patients. Call (801) 810-4097 and visit Please email to sign up for our monthly newsletter to stay up to date with the rapidly evolving  genetic and genomic testing space!


The Center for Genomic

The Center for Genomic Interpretation (CGI) is an independent 501(c)(3) nonprofit organization with the mission to save and improve lives through encouraging careful stewardship of clinical genetics, genomics and precision medicine. Too frequently the precision medicine goals of patients and their providers are unknowingly thwarted by inaccurate or ineffective genetic or genomic testing. We facilitate the realization of value from among the confusing scramble of the new precision medicine era. The CGI team consists of clinical genetics and genomics scientific leaders, healthcare policy veterans, experienced business professionals, and others dedicated to helping stakeholders achieve the vision and promise of precision medicine.  CGI offers a range of programs and services targeted to all stakeholders including patients, providers, payers, pharmaceutical developers, policy makers and laboratories.

The post Support for VALID in the FDA Safety and Landmark Advancement Act Draft of 2022 appeared first on Center for Genomic Interpretation.

The post Support for VALID in the FDA Safety and Landmark Advancement Act Draft of 2022 appeared first on Center for Genomic Interpretation.